Sarah E. Yentz

Sarah E. Yentz

Oncology | Internal Medicine
7500 Challis Rd
Entrance1, Level 1
Brighton, MI 48116

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer.

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer.

Journal: bioRxiv : the preprint server for biology
Published: July 30, 2026

Supporting graduate medical trainees through parental leave: Best practices for program success.

Supporting graduate medical trainees through parental leave: Best practices for program success.

Journal: Journal of hospital medicine
Published: April 01, 2026

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Journal: JCO precision oncology
Published: September 16, 2025

Bridging Language Barriers in Healthcare: An Innovative Curriculum for Teaching Medical Students to Work Effectively with Medical Interpreters.

Bridging Language Barriers in Healthcare: An Innovative Curriculum for Teaching Medical Students to Work Effectively with Medical Interpreters.

Journal: MedEdPublish (2016)
Published: June 05, 2025

Controversies in metastatic hormone-sensitive prostate cancer.

Controversies in metastatic hormone-sensitive prostate cancer.

Journal: Cancer
Published: February 26, 2025

Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.

Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.

Journal: Cancer immunology, immunotherapy : CII
Published: December 07, 2023

Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma.

Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma.

Journal: Ophthalmic plastic and reconstructive surgery
Published: May 19, 2023

A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.

A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.

Journal: The Journal of urology
Published: November 01, 2022

Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma.

Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma.

Journal: Cancers
Published: October 04, 2022

Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis.

Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis.

Journal: JACC. CardioOncology
Published: June 01, 2022

Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma.

Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma.

Journal: Frontiers in oncology
Published: January 16, 2022

Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Journal: International journal of molecular sciences
Published: November 19, 2021
Showing 1-12 of 25

Last Updated: 09/26/2026